[이코노믹리뷰=황진중 기자] The Ministry of Health and Welfare emphasized that the research funds for the celltrion (068270) treatment candidate were legally supported in accordance with regulations.
The Ministry of Health and Welfare announced on the 30th that the time when Celltrion was confirmed as a support target for the COVID-19 treatment clinical support project was before it was designated as a ‘large company’ under the National R&D Innovation Act.
According to the explanation, the timing of the clinical project selection and agreement is in August 2020 for phase 1/2 and January this year for phase 3. Celltrion was excluded from mid-sized companies on May 1st.
In principle, for national R&D projects, the private contribution for R&D expenses is determined according to the size of the R&D institution at the time of the conclusion of the agreement in accordance with the relevant laws, the National R&D Innovation Act and the regulations on the management of national R&D projects.
The Ministry of Health and Welfare explained that Celltrion applied for all support related to the Phase 1/2/3 clinical trial plan, and as a result of the selection evaluation, it applied first to the Phase 1/2 clinical trial according to the opinion that it is appropriate to apply after seeing the results of the Phase 1/2 clinical trial. did.
An official from the Ministry of Health and Welfare said, “Celltrion’s Corona 19 treatment ‘Rekkorna (generic name legdanvirab, candidate material name CT-P59)’, developed through government support, has received official product approval from the Ministry of Food and Drug Safety, and is actively promoting the treatment of COVID-19 patients. “Until the development of a domestic COVID-19 treatment/vaccine is completed, the government plans to actively support development companies in all directions, including clinical cost support, clinical participant recruitment, and sample analysis,” he said.
.
